EA200501645A1 - Ингибиторы гликогенфосфорилазы, представляющие собой амиды пирролопиридин-2-карбоновых кислот - Google Patents

Ингибиторы гликогенфосфорилазы, представляющие собой амиды пирролопиридин-2-карбоновых кислот

Info

Publication number
EA200501645A1
EA200501645A1 EA200501645A EA200501645A EA200501645A1 EA 200501645 A1 EA200501645 A1 EA 200501645A1 EA 200501645 A EA200501645 A EA 200501645A EA 200501645 A EA200501645 A EA 200501645A EA 200501645 A1 EA200501645 A1 EA 200501645A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
glycogen
pyrrophyridine
phosphorilase
amyda
Prior art date
Application number
EA200501645A
Other languages
English (en)
Other versions
EA009215B1 (ru
Inventor
Стюарт Эдуард Брэдли
Томас Мартин Крулле
Питер Джон Мюррей
Мартин Джеймс Проктер
Роберт Джон Роули
Колин Питер Сэмбрук Смит
Джерард Хью Томас
Карен Лесли Шофильд
Original Assignee
Прозидион Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Прозидион Лимитед filed Critical Прозидион Лимитед
Publication of EA200501645A1 publication Critical patent/EA200501645A1/ru
Publication of EA009215B1 publication Critical patent/EA009215B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Соединения, представленные формулой (I), или их фармацевтически приемлемые соли, являющиеся ингибиторами гликогенфосфорилазы и полезные в профилактическом или терапевтическом лечении диабета, гипергликемии, гиперхолестеринемии, гиперинсулинемии, гиперлипидемии, гипертензии, атеросклероза или ишемии тканей, например ишемии миокарда, и в качестве кардиопротекторов.
EA200501645A 2003-05-21 2004-05-20 Ингибиторы гликогенфосфорилазы, представляющие собой амиды пирролопиридин-2-карбоновых кислот EA009215B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47237503P 2003-05-21 2003-05-21
US55125604P 2004-03-08 2004-03-08
PCT/US2004/016243 WO2004104001A2 (en) 2003-05-21 2004-05-20 Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase

Publications (2)

Publication Number Publication Date
EA200501645A1 true EA200501645A1 (ru) 2006-06-30
EA009215B1 EA009215B1 (ru) 2007-12-28

Family

ID=33479321

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501645A EA009215B1 (ru) 2003-05-21 2004-05-20 Ингибиторы гликогенфосфорилазы, представляющие собой амиды пирролопиридин-2-карбоновых кислот

Country Status (16)

Country Link
EP (1) EP1636224B1 (ru)
JP (2) JP2006528702A (ru)
KR (1) KR101120935B1 (ru)
AT (1) ATE473974T1 (ru)
AU (1) AU2004240946B8 (ru)
BR (1) BRPI0410445B1 (ru)
CA (1) CA2525502C (ru)
DE (1) DE602004028122D1 (ru)
EA (1) EA009215B1 (ru)
IL (1) IL171851A (ru)
MA (1) MA27809A1 (ru)
MX (1) MXPA05012547A (ru)
NO (1) NO332265B1 (ru)
NZ (1) NZ543482A (ru)
UA (1) UA84146C2 (ru)
WO (1) WO2004104001A2 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
JP4795965B2 (ja) * 2003-11-12 2011-10-19 エルジー・ライフ・サイエンシーズ・リミテッド メラノコルチン受容体のアゴニスト
US7884112B2 (en) 2004-03-08 2011-02-08 Stuart Edward Bradley Pyrrolopyridine-2-carboxylic acid hydrazides
JP2007531744A (ja) * 2004-04-05 2007-11-08 武田薬品工業株式会社 ６−アザインドール化合物
DE102004054634A1 (de) * 2004-11-12 2006-05-18 Schwarz Pharma Ag Azaindolcarboxamide
GB0425919D0 (en) * 2004-11-25 2004-12-29 Prosidion Ltd Indole-2-carboxylic acid amides
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
US20090099176A1 (en) 2004-12-02 2009-04-16 Thomas Martin Krulle Pyrrolopyridine-2-carboxylic acid amides
ES2309822T3 (es) 2004-12-02 2008-12-16 Prosidion Limited Derivado de amida del acido pirrolopiridina-2-carboxilico util como inhibidor de la glucogeno-fosforilasa.
CN101331115A (zh) * 2005-10-21 2008-12-24 沃泰克斯药物股份有限公司 调控离子通道的衍生物
KR101015666B1 (ko) * 2005-12-16 2011-02-22 에프. 호프만-라 로슈 아게 Ｈ3 수용체 조절제로서 피롤로[2,3-ｂ]피리딘 유도체
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US20100076037A1 (en) * 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
FR2911605B1 (fr) 2007-01-19 2009-04-17 Sanofi Aventis Sa Derives de pyrrolopyridine-2-carbowamides, leur preparation et leur application en therapeutique
DE102007012284A1 (de) 2007-03-16 2008-09-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035333A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035334A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007042154A1 (de) 2007-09-05 2009-03-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel
US8785489B2 (en) 2008-10-17 2014-07-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as MMP-13 inhibitors
UY32940A (es) 2009-10-27 2011-05-31 Bayer Cropscience Ag Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
CA2835216A1 (en) 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
EP2714648B1 (en) 2011-05-31 2017-08-16 Theravance Biopharma R&D IP, LLC Neprilysin inhibitors
WO2012166390A1 (en) * 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
IN2015DN01061A (ru) 2012-08-17 2015-06-26 Bayer Cropscience Ag
CN103626825B (zh) * 2013-09-30 2015-10-07 承德医学院 靶向肝脏的糖原磷酸化酶抑制剂胆酸类衍生物、其制备方法及医药用途
US20160318897A1 (en) 2013-12-18 2016-11-03 Basf Se Azole compounds carrying an imine-derived substituent
CA3163206A1 (en) * 2019-11-27 2021-06-03 Riken G9a inhibitor
JP2023550591A (ja) 2020-11-02 2023-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＥＧＦＲ阻害薬としての置換１Ｈ－ピラゾロ［４，３－ｃ］及び誘導体
KR20230169977A (ko) * 2021-03-10 2023-12-18 빈시어 바이오사이언시스, 인크. Usp30 억제제 및 이의 용도
WO2023165168A1 (zh) * 2022-10-27 2023-09-07 常州大学 吡唑类衍生物作为β2肾上腺素受体别构调节剂,拮抗剂和激动剂的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4619915A (en) * 1984-10-19 1986-10-28 Pfizer Inc. Peptide-substituted heterocyclic immunostimulants
IL88619A0 (en) * 1987-12-15 1989-07-31 Pfizer Non-peptidic renin inhibitors
EP0712844A4 (en) * 1994-06-06 1996-11-06 Green Cross Corp NOVEL CARBOXYLIC ACID COMPOUND WITH FUSED CORE OR SALT THEREOF, AND ITS USE IN MEDICINE
JP3314938B2 (ja) * 1995-06-06 2002-08-19 ファイザー・インコーポレーテッド グリコーゲンホスホリラーゼ抑制剤としての置換されたｎ−（インドール−２−カルボニル）−グリシンアミド類および誘導体
MY114711A (en) * 1995-06-06 2002-12-31 Pfizer Substituted n-(indole-2-carbonyl)-b-alanmamides and derivatives as antidiabetic agents
AP9600817A0 (en) * 1995-06-06 1996-07-31 Pfizer Novel cryatal form of anhydrous 7-( [1A,5A,6A]-6-amino3-3-azabicyclo [3.1.0.] hex-3-yl) -6-fluro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1, 8-naphthyridine-3-carboxylic acid, methanesulfonic acid salt.
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
EP1088824B1 (en) * 1999-09-30 2004-01-07 Pfizer Products Inc. Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
WO2004039807A1 (en) * 2002-10-30 2004-05-13 Merck Frosst Canada & Co. Pyridopyrrolizine and pyridoindolizine derivatives

Also Published As

Publication number Publication date
NZ543482A (en) 2009-02-28
EP1636224A2 (en) 2006-03-22
KR20060069792A (ko) 2006-06-22
UA84146C2 (ru) 2008-09-25
JP2011252005A (ja) 2011-12-15
DE602004028122D1 (de) 2010-08-26
AU2004240946B2 (en) 2011-09-08
AU2004240946B8 (en) 2012-01-12
CA2525502A1 (en) 2004-12-02
BRPI0410445A (pt) 2006-05-30
WO2004104001A2 (en) 2004-12-02
JP5669691B2 (ja) 2015-02-12
AU2004240946A1 (en) 2004-12-02
NO332265B1 (no) 2012-08-13
KR101120935B1 (ko) 2012-03-05
BRPI0410445B1 (pt) 2017-11-28
CA2525502C (en) 2012-12-18
WO2004104001A3 (en) 2005-03-03
EA009215B1 (ru) 2007-12-28
ATE473974T1 (de) 2010-07-15
EP1636224B1 (en) 2010-07-14
NO20055305L (no) 2005-12-15
MXPA05012547A (es) 2006-05-25
IL171851A (en) 2011-08-31
JP2006528702A (ja) 2006-12-21
MA27809A1 (fr) 2006-03-01
NO20055305D0 (no) 2005-11-10

Similar Documents

Publication Publication Date Title
EA200501645A1 (ru) Ингибиторы гликогенфосфорилазы, представляющие собой амиды пирролопиридин-2-карбоновых кислот
DE602005013275D1 (de) Pyrrolopyridin-2-karbonsäureamide
ATE483708T1 (de) Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
EA200501095A1 (ru) Фенилацетамиды и их применение в качестве модуляторов глюкокиназы
TW200718424A (en) Novel compounds of amino sulfonyl derivatives
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
JO2282B1 (en) Oxazole derivatives
BRPI0517567A (pt) composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo, composição farmacêutica, usos de um composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo e de uma composição farmacêutica, e, processo para preparar um composto
DE60315336D1 (de) Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv)
EA200501936A1 (ru) Производные пиридо[2,1-a]изохинолина в качестве ингибиторов dpp-iv
NO20081846L (no) Bifenylderivater og deres anvendelse ved behandling av hepatitt C
EA200601747A1 (ru) Три(цикло)замещённые амидные соединения
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
NO20082445L (no) Neuropeptid-2 reseptor-agonister
EA200701808A1 (ru) Производные тетрагидроиндолона и тетрагидроиндазолона
ATE384058T1 (de) Thiazolderivate
NO20056010L (no) Biaryloksymetylaren-karboksylsyrer
NO20072608L (no) Biaryloksymetylarenkarboksylsyrer
NO20052699L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
WO2005085194A3 (en) Indole-2-carboxylic acid hydrazides as glycogen phosphorylase inhibitors
WO2006004903A3 (en) 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
UA90843C2 (ru) Соединения три(цикло)-замещенных амидов
UA90039C2 (en) Neuropeptide-2 receptor-agonists
IL160604A0 (en) C2-disubstituted indan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU